These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 9836396

  • 1. [Iron chelation in 1998].
    de Montalembert M.
    Transfus Clin Biol; 1998 Oct; 5(5):353-6. PubMed ID: 9836396
    [Abstract] [Full Text] [Related]

  • 2. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 3. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 4. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 5. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Apr 10; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A risk-benefit assessment of iron-chelation therapy.
    Porter JB.
    Drug Saf; 1997 Dec 10; 17(6):407-21. PubMed ID: 9429839
    [Abstract] [Full Text] [Related]

  • 10. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun 10; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 11. Long term deferiprone chelation therapy.
    Hoffbrand VA, Wonke B.
    Adv Exp Med Biol; 2002 Jun 10; 509():127-39. PubMed ID: 12572992
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003 Jun 10; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 14. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Jun 10; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I.
    Adv Ther; 2008 Aug 10; 25(8):725-42. PubMed ID: 18704280
    [Abstract] [Full Text] [Related]

  • 17. Iron chelation with oral deferiprone in patients with thalassemia.
    Stella M, Pinzello G, Maggio A.
    N Engl J Med; 1998 Dec 03; 339(23):1712; author reply 1713-4. PubMed ID: 9867539
    [No Abstract] [Full Text] [Related]

  • 18. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 19. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A, Khoriaty E, Musallam KM, Taher AT.
    Am J Hematol; 2010 Oct 18; 85(10):782-6. PubMed ID: 20721892
    [No Abstract] [Full Text] [Related]

  • 20. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun 18; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.